drugset / Trial / NCT02544932
Pleotropic Effect of New Oral Anticoagulants
RandomizedParallel-groupOpen-labelTreatment
Summary
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran | Unknown | 110 mg | Oral |
| Subject | Dabigatran | Unknown | 150 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Comparator | Warfarin | Small molecule | — | — |